HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety w wieku 19 lat lub starsze.
- •Potwierdzone przedrakowe zmiany szyjki macicy (CIN2/3).
- •Zakażenie wirusem HPV typu 16.
- •U kobiet z HIV: możliwość skutecznego leczenia antyretrowirusowego i kontrola wirusa.
- •Wiek 19 lat lub więcej (ze względu na przepisy prawne).
✗ Disqualifies
- •Stan zdrowia niepozwalający na udział w badaniu (np. bardzo niski poziom białych krwinek, płytek krwi, hemoglobiny).
- •Bardzo krótki przewidywany czas życia (< 4 miesiące).
- •Stan ogólny pacjenta (performance status) wyższy niż 1.
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- July 2, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (2)
University of Alabama at Birmingham
Birmingham, United States
Johns Hopkins University
Baltimore, United States
Trial contact
Kimberly Levinson, MD
Ashish Solanki, RN
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.